A Phase 1b, Open Label, Dose Finding Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Axitinib (Ag-013736) In Combination With Pembrolizumab (Mk-3475) In Patients With Advanced Renal Cell Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Axitinib (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 01 May 2017 Planned End Date changed from 1 Sep 2018 to 1 Apr 2018.
- 01 Dec 2016 Planned End Date changed from 1 Mar 2017 to 1 Sep 2018.